GNCA News and Press, Genocea Biosciences Inc. From 11/10/21

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at...

Genocea Biosciences, Inc. (GNCA) Q3 2021 Earnings Conference Call October 28, 2021 8:30 AM ET Company Participants Dan Ferry – Investor Relations-LifeSci Advisors Chip Clark – President and Chief Executive Officer Diantha Duvall – Chief Financial Officer Tom Davis –...

Genocea Biosciences (NASDAQ:GNCA): Q3 GAAP EPS of -$0.05 beats by $0.16. Revenue of $1.64M (+264.4% Y/Y) Press Release For further details see: Genocea Biosciences EPS beats by $0.16

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36 th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosc...

AB, ABEV, ABMD, ADS, AEP, AGCO, ALDX, ALIM, ALNY, AMT, AOS, ARGX, ASX, OTCPK:ATGFF, ATI, AVNT, BAX, BC, OTCQX:BDRBF, BPMC, BTU, BUD, CARR, CAT, CBRE, CFR, CG, CHKP, CMCSA, CMS, CNSL, CNX, COHU, COOP, COR, CPG, CRS, CVEO, CWT, CX, OTCPK:DASTY, DBD, DQ, OTCPK:EADSF, EXP, FLWS, GNCA, GPI, GTX, G...

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October...

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October. Scient...

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA...

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September. ...

Genocea Biosciences, Inc. (GNCA) Q2 2021 Earnings Conference Call July 29, 2021 08:30 AM ET Company Participants Dan Ferry - Investor Relations, LifeSci Advisors Chip Clark - President & Chief Executive Officer Diantha Duvall - Chief Financial Officer Tom Davis - Chief Medical Officer Jes...